14 Months on an Epithalon + GHK-Cu Longevity Stack: What Actually Happened is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.
Last March, I was sitting across from my prescriber in Austin, a longevity-focused physician named Dr. Reyes, reviewing my third quarterly blood panel since starting this protocol. He scrolled through the numbers, paused, and said something that stuck with me: “Your labs look exactly the same as baseline. That’s actually what I want to see.” When I pressed him on whether “nothing changed” meant the stack wasn’t working, he leaned back. “The sleep data is the interesting part. Everything else is too early to call, and anyone who tells you otherwise is selling something.”
That exchange captures the honest reality of running an Epithalon plus GHK-Cu longevity stack for 14 months. Some things have clearly shifted. Most things haven’t. And the temptation to over-attribute is constant.
This is the full write-up.
Compliance frame. Epithalon is a synthetic tetrapeptide not FDA-approved for any human indication. GHK-Cu appears in many OTC cosmetic formulations and as a compounded research peptide for prescribed topical or injectable use. Both are accessed through 503A compounding pharmacies for individual patient prescriptions based on prescriber clinical judgment. Both were placed on the 503A bulks list under FDA review in 2023. This is personal experience, not medical advice.
The Logic Behind Pairing These Two
The two peptides target different layers of the aging problem, which is the whole point of combining them.
Epithalon is theorized to modulate the pineal axis, circadian regulation, and possibly telomere-related cellular signaling. Most of the published human work comes from Russian research groups. The proposed mechanism sits upstream: think of it as an attempt to adjust the master clock rather than fix individual gears.
GHK-Cu is a copper-binding tripeptide naturally present in human plasma, with levels declining as you age. Published research shows effects on collagen synthesis, antioxidant signaling, gene expression patterns associated with younger tissue, and various skin and wound healing parameters. It works downstream, at the tissue level.
So in theory, Epithalon addresses systemic aging signaling while GHK-Cu handles tissue maintenance. Like pairing an operating system update with hardware repair.
Here’s the thing, though: the published evidence on combined use is essentially zero. This combination exists because longevity physicians extended mechanism-based reasoning into clinical practice. Reasonable? I think so. Proven? Not close.
The Actual Protocol
The dosing patterns are completely different because the peptides work on different timescales.
Epithalon:
- 10 mg subcutaneous, once daily
- 10 consecutive days, twice per year (20 total dosing days annually)
- Cycle 1 in January, Cycle 2 in July
GHK-Cu:
- Subcutaneous injectable: 2 mg once daily, 5 days a week, year-round
- Topical: 2 percent serum applied twice daily to face and neck
The two never overlap in a single injection session. Epithalon is a brief, intense burst. GHK-Cu is the steady background hum. They coexist in the same stack without competing.
What I Track (and Why It Matters)
Over 14 months I’ve maintained:
- Standard labs quarterly: CBC, CMP, lipid panel, fasting glucose, fasting insulin, A1C, inflammatory markers
- DEXA body composition at baseline and 12 months
- Telomere length at baseline and 12 months
- Continuous sleep architecture via wearable
- Weekly subjective wellbeing ratings
- Monthly photographs under consistent lighting
The tracking matters more than the protocol, honestly. Without it you’re just guessing.
What Changed, What Didn’t, and What I Can’t Prove
Sleep is the standout. This has been the most consistent and objectively measurable shift. Deep sleep increased approximately 18 percent versus a 6-month pre-protocol baseline. REM trended up slightly too. The improvement seems to build during Epithalon cycles and partially persist through the months between them. My wearable data shows a clear pattern. Whether Epithalon caused it? I can’t isolate it perfectly. I’ve also been more disciplined about circadian alignment and modestly reduced caffeine. But the timing correlation with Epithalon cycles is hard to ignore.
Skin improvement is real but slow. The GHK-Cu, both injectable and topical, has produced visible changes in skin texture and tone on my face and neck. Cumulative, not dramatic. Other people have noticed without prompting. Photographic comparison confirms it. This is the one area where I feel reasonably confident in attribution, given that GHK-Cu’s dermal effects have published support and the topical application is directly at the target tissue.
Body composition: a wash, basically. DEXA at 12 months showed body fat down 1.2 percent, lean mass up about 0.6 pounds. Both figures fall squarely within what consistent training and higher protein intake could explain. I’m not crediting the peptides here.
Labs: perfectly boring. Lipids, glucose, insulin, A1C, inflammatory markers, CBC, CMP, all hovering in the same range as baseline across four quarterly panels. No drift in either direction. This is what Dr. Reyes meant by “that’s what I want to see.” Stability means the intervention isn’t causing harm.
Telomere length: noise. The 12-month measurement was within measurement error of baseline. I’m repeating at 24 months. The Russian Epithalon literature includes telomere claims, but replication is thin. I’m not drawing any conclusions from a single data point on a notoriously variable biomarker.
Subjective wellbeing. Weekly ratings averaged about half a point higher than the pre-protocol period. This is the weakest signal in the dataset. Could be placebo. Could be the better sleep. Could be that I feel good about doing something proactive. I log it but don’t lean on it.
Side Effects Over 14 Months
Brief warmth at injection sites, resolving within an hour. That’s it.
No systemic side effects. No mood changes. No appetite shifts. No energy spikes or crashes. No sleep onset disruption (which I specifically watched for during Epithalon cycles). Nothing in any subjective domain I track.
The combined safety profile has been clean. This aligns with available safety data on each peptide individually, though the combination itself is unstudied, so I hold that observation loosely.
Where My Skepticism Lives
I want to be clear about what I don’t trust in this space.
I don’t trust my own attribution instincts. The sleep data is compelling. Everything else could be coincidence, confounders, or confirmation bias. Running a protocol and tracking outcomes doesn’t make you a controlled trial.
I don’t trust the long-term safety picture. Both peptides have reasonable short and medium-term safety profiles. But “no one has documented problems in 14 months” is not the same as “safe over a decade.” The data simply isn’t mature enough.
I don’t trust telomere marketing. If someone is telling you a peptide will meaningfully extend your telomeres, they’re operating well beyond what published evidence supports. Telomere biology is wildly more complicated than the sales copy version.
I’m watching the regulatory situation. Both peptides sit on the 503A bulks list under FDA review. The compounded pathway through a licensed pharmacy with a prescriber relationship is the legitimate access route. Gray-market peptides purchased without a prescription are a different product with a different risk profile, full stop.
Why I Keep Going
The boring truth: the risk-to-reward math still works for me.
Low side effects. Modest cost. Plausible mechanisms. One clearly measurable improvement (sleep architecture) that has been consistent enough to suggest genuine biological activity. No red flags in 14 months of tracking.
I would not escalate this protocol. Not higher doses, not more frequent cycles, not longer continuous exposure. The conservative patterns I follow (Epithalon cycled per the original Russian research protocol, GHK-Cu at conservative daily dosing) represent the outer boundary of what I’m willing to defend given the current evidence base.
What It Costs
Annual breakdown:
- Epithalon: 2 cycles at roughly $185 each = $370
- GHK-Cu injectable: approximately $95/month = $1,140/year
- GHK-Cu topical serum: approximately $80 per 6 weeks = $700/year
Total: roughly $2,200 annually, not counting quarterly labs and prescriber visits that I’d be doing anyway for general longevity monitoring.
That’s comparable to a moderately premium supplement stack or a monthly massage habit. Not trivial, but not extravagant for something I consider a real input rather than a hopeful gesture.
Sourcing
Both compounded prescriptions have been filled through this peptide source, a compounded telehealth pharmacy working with licensed 503A compounding pharmacies that handles peptide therapy for my prescriber’s patients. Lot labeling has been consistent. Beyond-use dating clear. Sterility statements available on request.
Other 503A pharmacies compound both peptides. The right one is whichever your prescriber has vetted for quality and concentration consistency.
Where I Land After 14 Months
Something is happening. The magnitude is modest. The side effect profile is clean. The cost is manageable.
This stack is not the foundation of my health. Sleep, training, nutrition, and standard preventive care are the foundation. The peptide protocol is a small addition, like adding another floor to a building that already has solid framing. Without the framing, the extra floor is pointless.
I plan to run at least another 12 months and write a 36-month update with the next telomere measurement, continued lab data, and a longer sleep architecture dataset.
For anyone considering a similar approach: get your fundamentals dialed first. Work with a prescriber who actually examines your labs, not just signs off on orders. Use a licensed 503A pharmacy. Dose per published patterns, not internet bro-science maximums. Track honestly. And calibrate your expectations to what the evidence actually shows, not to what the marketing promises.
Not FDA-approved. Both Epithalon and GHK-Cu are prescribed off-label and prepared by licensed 503A pharmacies for individual patients based on clinical judgment. Personal experience, not medical advice.
Frequently Asked Questions
Can Epithalon and GHK-Cu be injected at the same time of day? They can, but I separate them. The Epithalon cycles are short (10 days, twice yearly) and I inject it in the morning. GHK-Cu goes in the evening on those overlap days. There’s no published interaction data, so separating them is just a precaution based on the absence of evidence rather than evidence of a problem.
How quickly did you notice the sleep improvements? The first Epithalon cycle produced a noticeable shift in deep sleep by about day 5 or 6, according to my wearable data. The effect partially persisted after the 10-day cycle ended, then built further during the second cycle six months later. GHK-Cu alone didn’t produce an obvious sleep signal.
Is the GHK-Cu topical serum necessary if you’re already injecting? Probably not necessary, but the topical targets skin directly while the injectable works systemically. I think of it as local plus systemic coverage. The topical alone has published support for skin effects. Whether adding the injectable on top provides additional skin benefit is unclear.
What would make you stop this protocol? Any unfavorable lab drift, any persistent side effect, or a regulatory change that removed these peptides from the 503A bulks list without an alternative legitimate access route. Also, if the 24-month data shows zero additional signal beyond what I see now, I’d seriously reconsider whether continued cost is justified.
Do you need a prescription for both peptides? Yes. Both require a prescriber relationship and are fulfilled through 503A compounding pharmacies as individual patient prescriptions. Buying either peptide without a prescription from a gray-market source means you have no assurance of identity, purity, or sterility.
Is this stack appropriate for someone in their 30s? That’s a conversation for your prescriber, not for me. GHK-Cu levels decline measurably with age, so the replacement rationale strengthens as you get older. Whether someone in their 30s gets meaningful benefit from either peptide is genuinely unclear. I started at 44.
What’s the minimum tracking you’d recommend if running this stack? Quarterly basic labs (CBC, CMP, lipids, fasting glucose and insulin) and a wearable that tracks sleep architecture. Without those, you’re flying blind and you’ll have no idea whether the protocol is doing something or doing nothing.
